Table 2.
Adverse Events Reported by More Than 5% of Participants in Either Treatment Group
| No. (%) of Study Participantsa |
|||
|---|---|---|---|
| Adverse Events | Latrepirdine (n=46) | Placebo (n=44) | P Value |
| Falls | 4 (9) | 7 (16) | .35 |
| Headache | 7 (15) | 3 (7) | .32 |
| Dizziness | 3 (7) | 6 (14) | .31 |
| Nausea | 3 (7) | 5 (11) | .48 |
| Chorea | 3 (7) | 3 (7) | >.99 |
| Depression | 2 (4) | 3 (7) | .67 |
| Nasopharyngitis | 2 (4) | 3 (7) | .67 |
| Somnolence | 3 (7) | 1 (2) | .62 |
| Irritability | 1 (2) | 3 (7) | .36 |
| Increased electrocardiogram QTc interval | 0 | 3 (7) | .11 |
| Diarrhea | 0 | 3 (7) | .11 |
a
Percentages do not total 100% owing to rounding.